

---

## Remuneration report 2025 for Initiator Pharma A/S

Initiator Pharma's Remuneration Report 2025 has now been published and is available on the company's home page.

<http://initiatorpharma.com/investors/financial-reports/>

For additional information about Initiator Pharma, please contact:

---

Claus Elsborg Olesen, CEO  
Telephone: +45 6126 0035  
E-mail: [ceo@initiatorpharma.com](mailto:ceo@initiatorpharma.com)

### About Initiator Pharma

---

Initiator Pharma A/S is a Danish clinical stage emerging pharma company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma's pipeline consists of one clinical stage assets – pudafensine – and one preclinical asset. With pudafensine the company has reported positive, statistically significant and clinically relevant efficacy data in a Phase IIb clinical trial with patients suffering from ED.

Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye Sweden AB is the company's Certified Adviser. For more information, please visit [www.initiatorpharma.com](http://www.initiatorpharma.com).

### Attachments

---

[Remuneration report 2025 for Initiator Pharma A/S](#)  
[2025 Remuneration Report Final](#)